Regenetp (STU:NJT) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Regenetp Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Regenetp's annualized Gross Profit for the quarter that ended in Mar. 2023 was €0.00 Mil. Regenetp's average Total Assets over the quarter that ended in Mar. 2023 was €19.21 Mil. Therefore, Regenetp's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 was 0.00%.

Regenetp Gross-Profit-to-Asset % Historical Data

The historical data trend for Regenetp's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Gross-Profit-to-Asset % Chart

Regenetp Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

1.04

4.58

10.94

13.85

0.76

Regenetp Quarterly Data
	Apr18	Jul18	Oct18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															3.31	-0.73	-	-	-

Competitive Comparison of Regenetp's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Regenetp's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenetp's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Regenetp's Gross-Profit-to-Asset % falls into.

Regenetp Gross-Profit-to-Asset % Calculation

Regenetp's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	0.187	/	( (27.593	+	21.568)	/ 2 )
	=	0.187	/	24.5805
	=	0.76 %

Regenetp's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Mar. 2023 ))	/ count )
	=	0	/	( (21.568	+	16.858)	/ 2 )
	=	0	/	19.213
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Regenetp Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Regenetp's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenetp (STU:NJT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

RGTPQ:USA

Address

1960 South 4250 West, Salt Lake City, UT, USA, 84104

Website

https://www.polarityte.com

Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines